{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:21:39Z","timestamp":1792012899366,"version":"4.4.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":2043,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5,19]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The aim of this study was to evaluate prospectively cytokine levels and disease activity in juvenile idiopathic arthritis (JIA) patients treated with and without tumour necrosis factor (TNF)-\u03b1 inhibitors. TNF-\u03b1 inhibitor-naive JIA subjects were followed prospectively for 6 months. Cytokine levels of TNF-\u03b1, interleukin (IL)\u22121\u03b2, IL-6, IL-8, IL-10 and IL-17 were measured at baseline for JIA subjects and healthy controls (HCs). Cytokine levels were then measured at four time-points after initiation of TNF-\u03b1 inhibition for anti-TNF-\u03b1-treated (anti-TNF) JIA subjects, and at two subsequent time-points for other JIA (non-TNF) subjects. JIA disease activity by Childhood Health Assessment Questionnaire (CHAQ) disability index\/pain score and physician joint count\/global assessment was recorded. Sixteen anti-TNF, 31 non-TNF and 16 HCs were analysed. Among JIA subjects, those with higher baseline disease activity (subsequent anti-TNFs) had higher baseline TNF-\u03b1, IL-6 and IL-8 than those with lower disease activity (non-TNFs) (P\u2009&amp;lt;\u20090\u00b705). TNF-\u03b1 and IL-10 increased, and IL-6 and IL-8 no longer remained significantly higher after TNF-\u03b1 inhibitor initiation in anti-TNF subjects. Subgroup analysis of etanercept versus adalimumab-treated subjects showed that TNF-\u03b1 and IL-17 increased significantly in etanercept but not adalimumab-treated subjects, despite clinical improvement in both groups of subjects. JIA subjects with increased disease activity at baseline had higher serum proinflammatory cytokines. TNF-\u03b1 inhibition resulted in suppression of IL-6 and IL-8 in parallel with clinical improvement in all anti-TNF-treated subjects, but was also associated with elevated TNF-\u03b1 and IL-17 in etanercept-treated subjects.<\/jats:p>","DOI":"10.1111\/cei.12782","type":"journal-article","created":{"date-parts":[[2016,3,2]],"date-time":"2016-03-02T15:57:28Z","timestamp":1456934248000},"page":"308-317","source":"Crossref","is-referenced-by-count":43,"title":["The impact of disease activity and tumour necrosis factor-\u03b1 inhibitor therapy on cytokine levels in juvenile idiopathic arthritis"],"prefix":"10.1093","volume":"184","author":[{"given":"H M","family":"Walters","sequence":"first","affiliation":[{"name":"Department of Pediatric Rheumatology, Cohen Children's Medical Center, North-Shore-Long Island Jewish Health System, Lake Success, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T J A","family":"Lehman","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Adams","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G D","family":"Kalliolias","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA"},{"name":"Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, USA"},{"name":"Department of Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y S","family":"Zhu","sequence":"additional","affiliation":[{"name":"Clinical and Translational Science Center, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Santiago","sequence":"additional","affiliation":[{"name":"Clinical and Translational Science Center, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Sitaras","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Cunningham-Rundles","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T J","family":"Walsh","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, New York, NY, USA"},{"name":"Department of Medicine, Weill Cornell Medical College\/New York Presbyterian Hospital, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S S","family":"Toussi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,4,13]]},"reference":[{"key":"2021111804092070700_cei12782-bib-0001","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/rheumatology\/39.4.432","article-title":"Tumour necrosis factor alpha and its soluble receptors in juvenile chronic arthritis","volume":"39","author":"Rooney","year":"2000","journal-title":"Rheumatology (Oxf)"},{"key":"2021111804092070700_cei12782-bib-0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-065X.2008.00626.x","article-title":"Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics","volume":"223","author":"Feldmann","year":"2008","journal-title":"Immunol Rev"},{"key":"2021111804092070700_cei12782-bib-0003","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1073\/pnas.73.2.381","article-title":"Partial purification of a serum factor that causes necrosis of tumors","volume":"73","author":"Green","year":"1976","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021111804092070700_cei12782-bib-0004","first-page":"255","article-title":"The effects of tumor necrosis factor on the production of interleukin-1 by macrophages","volume":"5","author":"Hoffman","year":"1986","journal-title":"Lymphokine Res"},{"key":"2021111804092070700_cei12782-bib-0005","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/00002281-199709000-00009","article-title":"Cytokines in juvenile rheumatoid arthritis","volume":"9","author":"De Benedetti","year":"1997","journal-title":"Curr Opin Rheumatol"},{"key":"2021111804092070700_cei12782-bib-0006","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF02247847","article-title":"Interleukin-1, \u22126, and \u22128 levels in juvenile chronic arthritis","volume":"16","author":"Ozen","year":"1997","journal-title":"Clin Rheumatol"},{"key":"2021111804092070700_cei12782-bib-0007","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s100670170100","article-title":"Cytokine levels in serum of patients with juvenile rheumatoid arthritis","volume":"20","author":"Yilmaz","year":"2001","journal-title":"Clin Rheumatol"},{"key":"2021111804092070700_cei12782-bib-0008","first-page":"2359","article-title":"Cytokine levels in serum and synovial fluid of patients with juvenile rheumatoid arthritis","volume":"21","author":"Madson","year":"1994","journal-title":"J Rheumatol"},{"key":"2021111804092070700_cei12782-bib-0009","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/rheumatology\/kep125","article-title":"Differential cytokine profiles in juvenile idiopathic arthritis subtypes revealed by cluster analysis","volume":"48","author":"Van den Ham","year":"2009","journal-title":"Rheumatology (Oxf)"},{"key":"2021111804092070700_cei12782-bib-0010","first-page":"493","article-title":"Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis","volume":"10","author":"De Benedetti","year":"1992","journal-title":"Clin Exp Rheumatol"},{"key":"2021111804092070700_cei12782-bib-0011","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrrheum.2009.209","article-title":"Oligoarticular and polyarticular JIA: epidemiology and pathogenesis","volume":"5","author":"Macaubas","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"2021111804092070700_cei12782-bib-0012","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/ard.2006.061853","article-title":"Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study","volume":"66","author":"de Jager","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2021111804092070700_cei12782-bib-0013","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1128\/CDLI.5.1.28-32.1998","article-title":"Age-dependent levels of select immunological mediators in sera of healthy children","volume":"5","author":"Sack","year":"1998","journal-title":"Clin Diagn Lab Immunol"},{"key":"2021111804092070700_cei12782-bib-0014","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm.3260","article-title":"How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy","volume":"19","author":"Schett","year":"2013","journal-title":"Nat Med"},{"key":"2021111804092070700_cei12782-bib-0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","article-title":"TNF biology, pathogenic mechanisms and emerging therapeutic strategies","volume":"12","author":"Kalliolias","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2021111804092070700_cei12782-bib-0016","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10067-014-2779-8","article-title":"A prospective study comparing infection risk and disease activity in children with juvenile idiopathic arthritis treated with and without tumor necrosis factor-alpha inhibitors","volume":"34","author":"Walters","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2021111804092070700_cei12782-bib-0017","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.1780371209","article-title":"Measurement of health status in children with juvenile rheumatoid arthritis","volume":"37","author":"Singh","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2021111804092070700_cei12782-bib-0018","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","article-title":"A new mathematical model for relative quantification in real-time RT\u2013PCR","volume":"29","author":"Pfaffl","year":"2001","journal-title":"Nucleic Acids Res"},{"key":"2021111804092070700_cei12782-bib-0019","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrrheum.2014.127","article-title":"IL-6 biology: implications for clinical targeting in rheumatic disease","volume":"10","author":"Calabrese","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"2021111804092070700_cei12782-bib-0020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1615\/CritRevImmunol.2014010694","article-title":"Transcriptional regulation of IL-10 and its cell-specific role in vivo","volume":"34","author":"MacKenzie","year":"2014","journal-title":"Crit Rev Immunol"},{"key":"2021111804092070700_cei12782-bib-0021","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.clim.2011.01.015","article-title":"Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues","volume":"139","author":"Bos\u00e8","year":"2011","journal-title":"Clin Immunol"},{"key":"2021111804092070700_cei12782-bib-0022","first-page":"253","article-title":"Relation of interleukin-6, TNF-alpha and interleukin-1alpha with disease activity and severity in juvenile idiopathic arthritis patients","volume":"58","author":"Sp\u00eerchez","year":"2012","journal-title":"Clin Lab"},{"key":"2021111804092070700_cei12782-bib-0023","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.7754\/Clin.Lab.2013.130734","article-title":"Proinflammatory cytokines in monitoring the course of disease and effectiveness of treatment with etanercept (ETN) of children with oligo- and polyarticular juvenile idiopathic arthritis (JIA)","volume":"60","author":"Kaminiarczyk-Pyzalka","year":"2014","journal-title":"Clin Lab"},{"key":"2021111804092070700_cei12782-bib-0024","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/00007890-199601270-00011","article-title":"Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome","volume":"61","author":"Eason","year":"1996","journal-title":"Transplantation"},{"key":"2021111804092070700_cei12782-bib-0025","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1158\/1078-0432.CCR-04-0730","article-title":"A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer","volume":"10","author":"Madhusudan","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2021111804092070700_cei12782-bib-0026","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/rheumatology\/kei090","article-title":"Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A","volume":"45","author":"Nowlan","year":"2006","journal-title":"Rheumatology (Oxf)"},{"key":"2021111804092070700_cei12782-bib-0027","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.4049\/jimmunol.155.10.5038","article-title":"Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration","volume":"155","author":"Suffredini","year":"1995","journal-title":"J Immunol"},{"key":"2021111804092070700_cei12782-bib-0028","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0145-2126(02)00082-6","article-title":"Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment","volume":"27","author":"Tsimberidou","year":"2003","journal-title":"Leuk Res"},{"key":"2021111804092070700_cei12782-bib-0029","first-page":"675108","article-title":"Ankylosing spondylitis and rheumatoid arthritis: serum levels of TNF-\u03b1 and its soluble receptors during the course of therapy with etanercept and infliximab","author":"Schulz","year":"2014","journal-title":"Biomed Res Int"},{"key":"2021111804092070700_cei12782-bib-0030","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/ard.62.6.561","article-title":"Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T Cells in ankylosing spondylitis during treatment with etanercept","volume":"62","author":"Zou","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2021111804092070700_cei12782-bib-0031","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/art.10847","article-title":"Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab","volume":"48","author":"Zou","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2021111804092070700_cei12782-bib-0032","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"2021111804092070700_cei12782-bib-0033","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1084\/jem.175.2.323","article-title":"Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors","volume":"175","author":"Aderka","year":"1992","journal-title":"J Exp Med"},{"key":"2021111804092070700_cei12782-bib-0034","first-page":"447","article-title":"Tumor necrosis factor (TNF) can paradoxically increase on etanercept treatment, occasionally contributing to TNF-mediated disease","volume":"34","author":"Bhatia","year":"2007","journal-title":"J Rheumatol"},{"key":"2021111804092070700_cei12782-bib-0035","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1186\/ar2772","article-title":"Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies","volume":"11","author":"Moran","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2021111804092070700_cei12782-bib-0036","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5114\/ceji.2014.42128","article-title":"Imbalance of Th17 and T-regulatory cells in peripheral blood and synovial fluid in treatment na\u00efve children with juvenile idiopathic arthritis","volume":"39","author":"Szyma\u0144ska-Ka\u0142u\u017ca","year":"2014","journal-title":"Cent Eur J Immunol"},{"key":"2021111804092070700_cei12782-bib-0037","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12674","article-title":"IL23R gene polymorphism with juvenile idiopathic arthritis and its association with serum IL-17A","author":"Emami","year":"2015","journal-title":"Int J Rheum Dis."},{"key":"2021111804092070700_cei12782-bib-0038","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/art.23291","article-title":"Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers","volume":"58","author":"Nistala","year":"2008","journal-title":"Arthritis Rheum"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.12782","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.12782","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cei.12782","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cei.12782","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/184\/3\/308\/41126272\/cei12782.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/184\/3\/308\/41126272\/cei12782.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T16:03:15Z","timestamp":1748793795000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/184\/3\/308\/6412140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,13]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,4,13]]},"published-print":{"date-parts":[[2016,5,19]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.12782","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2016,6]]},"published":{"date-parts":[[2016,4,13]]}}}